



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 29-12-2008

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 20-12-2008 TO BE PUBLISHED 30-12-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

**ENCL:**

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
**Karachi**

No.2/2/2003-F.Sec.

Dated: 29-12-2008

To,

Mr. Manzoor Ahmed  
Section Officer  
Cabinet Secretariat  
Cabinet Division  
Government of Pakistan  
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 20-12-2008 TO BE PUBLISHED 30-12-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23<sup>rd</sup> April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## **NEW APPLICATIONS FOR THE PATENTS**

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000

1459/2008	<b><u>15-12-2008</u></b> Janssen Pharmaceutica N.V., Belgium (Priority 17-12-07 USA)	“Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1”
1460/2008	Sanofi-Aventis France (Priority 18-12-07 France)	“Azetidine derivatives, preparation thereof and therapeutic use thereof”
1461/200	<b><u>16-12-2008</u></b> AstraZeneca AB, Japan (Priority 17-12-07 USA)	“New salt”
1462/2008	<b><u>17-12-2008</u></b> Borealis Technology Oy Finland (Priority 20-12-08 Europe)	“Process for coating a pipe with high throughput using multimodal ethylene copolymer, and coated pipes obtained thereof”
1463/2008	Borealis Technology Oy Finland (Priority 20-12-07 Europe)	“Process for coating a pipe with high throughput using multimodal ethylene copolymer, and coated pipes obtained thereof”
1464/2008	Borealis Technology Oy Finland (Priority 20-12-07 Europe)	“coated pipes having improved mechanical properties at elevated temperatures and a method of production thereof”
1465/2008	Borealis Technology Oy Finland (Priority 20-12-07 Europe)	“coated pipes having improved mechanical properties and a method of production thereof”
1466/2008	Boehringer Ingelheim International GmbH, Germany (Priority 19-12-07 USA)	“Viral polymerase inhibitors”
1467/2008	Glaxo Group Limited, United Kingdom (Priority 19-12-07 GB)	“Compounds which potentiate the AMPA receptor and uses thereof in medicine”

1468/2008	1. Prof. Dr. Muhammad Umar Khattak, 2. Naveed Ahmed Rawalpindi, Pakistan	“A mobile geographical information systems travel guide”
1469/2008	Kashif Farhan Sialkot Pakistan	“Method and apparatus for pressure and mass display in natural gas Vehicles”
1470/2008	1. Labopharm Inc., Canada 2. Labopharm Europe Limited, Ireland 3. Labopharm (Barbados) Limited, Barbados (Priority 17-12-07 USA)	“Misuse preventative controlled release formulation”
1471/2008	<b><u>18-12-2008</u></b> DSM IP Assets B.V Netherlands (Priority 20-12-07 EU)	“Process for the preparation of Melamine”
1472/2008	DSM IP Assets B.V Netherlands (Priority 20-12-07 Europe)	“Process for the Preparation of Melamine”
1473/2008	DSM IP Assets B.V Netherlands (Priority 20-12-07 Europe)	“Process for the Preparation of Melamine”
1474/2008	METHANOL CASALE S.A Switzerland (Priority 21-12-07 Europe)	“Radial isothermal chemical reactor”
1475/2008	Wyeth USA (Priority 21-12-07 USA)	“Genetically modified attenuated vesicular stomatitis virus. Compositions and methods of use thereof”
1476/2008	Telefonaktiebolaget LM Ericsson(publ) Sweden (Priority 20-12-07 USA)	“Method and arrangement in a telecommunication system”
1477/2008	AstraZeneca AB Sweden (Priority 20-12-07 USA)	“Carbomayl compounds as dgati inhibitors 190”

1478/2008	AstraZeneca AB Sweden (Priority 21-12-07 Sweden)	“New acetyl coenzyme a carboxylase (acc) inhibitors and uses in treatments of obesity and diabetes mellitus-087”
1479/2008	AstraZeneca AB Sweden (Priority 21-12-07 Sweden)	“Bicyclic derivatives for use in the treatment of androgen receptor associated conditions- 155”
1480/2008	Siemens VAI Metals Technologies GmbH & Co., Austria (Priority 21-12-07 Austria)	“Method and device for the coarse separation of solid particles from solids laden gases”
1481/2008	Bayer HealthCare AG, Germany (Priority 20-12-07 Germany)	“4-(4-cano-2-thioaryl) dihydropyrimidinones and their use”
1482/2008	Schering Corporation, USA (Priority 21-12-07 USA)	“C21 thioethers as glucocorticoid receptor agonists”
1483/2008	Schering Corporation, USA (Priority 21-12-07 USA)	“C20-C21 substituted glucocorticoid receptor agonists”
	<b><u>19-12-2008</u></b>	
1484/2008	Genelabs Technologies, Inc., USA (Priority 05-12-07 USA)	“Antiviral compounds”
1485/2008	Novartis AG, Switzerland (Priority 21-12-07 Europe)	“Pharmaceutical composition”
1486/2008	Glaxo Group Limited, United Kingdom (Priority 21-12-07 GB)	“Compounds”
1487/2008	Novartis AG, Switzerland (Priority 20-12-07 Europe)	“Organic compounds”
1488/2008	GlaxoSmithKline Biologicals S.A., Belgium (Priority 21-12-07 USA)	“Vaccine”

1489/2008	GlaxoSmithKline biologicals S.A Belgium (Priority 21-12-07 USA)	“Vaccines for malaria”
1490/2008	CECA S.A France (Priority 20-12-07 France)	“Lsx type zeolite having a controlled particle size distribution”
1491/2008	1.CECA S.A. 2.Institut Francais DU Petrole, France (Priority 20-12-07 France)	“Aggregate zeolitic adsorbents, their method of preparation and their uses”
1492/2008	1.CECA S.A. 2.Institut Francais DU Petrole, France (Priority 20-12-07 France)	“Aggregate zeolitic adsorbents, their method of preparation and their uses”
1493/2008	Unilever PLC., United Kingdom (Priority 11-1-08 India)	“Solid water soluble tea composition”
1494/2008	Merck Patent GmbH, Germany (Priority 21-12-07 Germany)	“S. specification”
	<b><u>20-12-2008</u></b>	
1495/2008	Abbott Laboratories, USA (Priority 21-12-07 USA)	“Child nutritional emulsions”
1496/2008	Abbott Laboratories, USA (Priority 21-12-07 USA)	“Induced viscosity nutritional emulsions a carbohydrate surfactant complex”
1497/2008	Abbott Laboratories, USA (Priority 20-12-07 USA)	“Stable Nutritional Power”
1498/2008	Abbott Laboratories, USA (Priority 20-12-07 USA)	“Stable Nutritional Power”

1499/2008	AstraZeneca AB, Sweden (Priority 21-12-07 USA)	“Novel crystalline form C of (2R)-(3-amino-2-fluoropropyl) phosphinic acid”
1500/2008	AstraZeneca AB, Sweden (Priority 21-12-07 USA)	“Novel process for making (2R)-(3-amino-2-fluoropropyl) phosphinic acid form A”
1501/2008	AstraZeneca AB, Sweden (Priority 21-12-07 USA)	“Novel crystalline form B of (2R)-(3-amino-2-fluoropropyl) phosphinic acid”
1502/2008	Astrazeneca AB, Sweden (Priority 20-12-08 USA)	“Bis-(sulfonylamino) derivatives in therapy 205”
1503/2008	MARICAP OY a Finish Company, Finland (Priority 21-12-07 Finland)	“Method in pneumatic material conveying system and a pneumatic material conveying system”
1504/2008	MARICAP OY a Finish Company, Finland (Priority 21-12-07 Finland)	“Method and apparatus in pneumatic material conveying system”
1505/2008	MARICAP OY a Finish Company, Finland (Priority 21-12-07 Finland)	“Method in pneumatic material conveying system and a pneumatic material conveying system”
1506/2008	MARICAP OY a Finish Company, Finland (Priority 21-12-07 Finland)	“Method and apparatus in pneumatic material conveying system”
1507/2008	MARICAP OY a Finish Company, Finland (Priority 21-12-07 Finland)	“Method and apparatus in pneumatic material conveying system”
1508/2008	MARICAP OY a Finish Company, Finland (Priority 21-12-07 Finland)	“Method and apparatus in pneumatic material conveying system”

1509/2008	MARICAP OY a Finish Company, Finland (Priority 21-12-07 Finland)	“Method and apparatus in pneumatic material conveying system”
1510/2008	MARICAP OY a Finish Company, Finland (Priority 21-12-07 Finland)	“Method and apparatus in pneumatic material conveying system”
1511/2008	MARICAP OY a Finish Company, Finland (Priority 21-12-07 Finland)	“Pneumatic material conveying system”

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

37/1999	Sanofi-Aventis France. Akzo Nobel NV, Netherland	“Novel synthetic hexadecasaccharide”  (A61K, 31/715)
---------	---	--

**139890**

The present invention relates to synthetic polysaccharide in form of pharmaceutically acceptable salt the anionic form of which corresponds to one of the formulae (I) to (V). These polysaccharide can be used in the treatment of pathologies related to a coagulation dysfunction.



490/2001


Pfizer Inc.,  
USA.

“3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3,2,1]octane”

(CO7D, 451/04)

**139892**

The present invention provides compound of the formula:



Wherein  $R^1$  is  $C_{3-6}$  cycloalkyl optionally substituted by one or more fluorine atoms, or  $C_{1-6}$  alkyl optionally substituted by one or more fluorine atoms, or  $C_{3-6}$  cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms;

and

$R^2$  is phenyl optionally substituted by one or more fluorine atoms, composition containing and the uses of, such compound.

668/2004


Pfizer Inc.,  
USA.

“Benzimidazolone compound”

(CO7D, 405/14)

**139893**

This invention provides a compound of the formula (1):



composition containing such compound and

the use of such compound for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome.

The compound have 5-HT<sub>4</sub> receptor agonistic activity, and thus is useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

821/2005

Vestergaard Frandsen  
SA.,  
Switzerland

“System with canopy and electrode for air cleaning”

(BO3C, 3/38, A47C, 29/00)

**139894**

System for separating particles from an environment, the system comprising a perforated screen and an ionisation electrode in the environment for creating an electrostatic potential between the electrode and the screen to attract the particles to the screen.

1320/2006

1. Sanofi-Aventis.  
France  
2. Akzo novel NV.,  
Netherlands

“Acid form of novel synthetic hexadecasaccharide”

(A61K, 31/715)

**139895**

The present invention relates to synthetic polysaccharide in acidic form, the anionic form of which corresponds to one of the formulae (I) to (V).

These polysaccharide can be used in the treatment of pathologies related to a coagulation dysfunction.

175/2007


Pfizer Inc.,  
USA.

“pharmaceutically acceptable salt and solvate of 3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3,2,1]octane”

(CO7D, 451/04)

**139896**

The present invention provides pharmaceutically acceptable salt or solvate of compound of the formula:



wherein

R<sup>1</sup> is C<sub>3-6</sub> cycloalkyl optionally substituted by one or more fluorine atoms, or C<sub>1-6</sub> alkyl optionally substituted by one or more fluorine atoms, or C<sub>3-4</sub> cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms;

and

R<sup>2</sup> is phenyl optionally substituted by one or more fluorine atoms; in combination with one or more additional therapeutic agent.

176/2007

Pfizer Inc.,  
USA.

“Pharmaceutically acceptable salt and solvate of n-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1, 2,4-triazol-4-yl)-exo-8-azabicyclo[3,2,1]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide”

(CO7D, 451/04)


**139897**

The present invention relates to a

pharmaceutically acceptable salt and solvate of N-{(1S)-3[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide, its use as antagonists in the treatment of infection by HIV and related retrovirus.

406/2007

Pfizer Inc.,  
USA.




“Pharmaceutically acceptable salt of benzimidazolone compound”

(CO7D, 405/14)

**139898**

This invention provides pharmaceutically acceptable salt of a compound of the formula (I)

Wherein

Het represents a group of formula ,

said heterocyclic group being

unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents a<sup>1</sup>

and composition containing such compound used for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional

dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome.

These compound have 5-HT<sub>4</sub> receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

XXXXXXXXXX

**SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139560	SmithKline Beecham Corporation., USA	812/1998
139561	Janssen Pharmaceutica N.V. Belgium	250/2002
139562	Glaxo Group Limited., United Kingdom	461/2002
139563	GlaxoSmithKline Biologicals S.A. and Glaxo Group Limited. United Kingdom	664/2002
139564	Alizyme Therapeutics Limited. United Kingdom	753/2002
139565	Pharmacia & Upjohn Company. USA	988/2002
139566	Wyeth Holdings Corporation. USA	769/2006

**(MRS. YASMEEN ABBASI)**  
**CONTROLLER OF PATENTS**  
Tel: 9215488